• Safety and toxicity [ Designated as safety issue: Yes ]
• Disease response (complete or partial response) or clinical benefit (stable disease for > 6 months) as measured by RECIST criteria [ Designated as safety issue: No ]
• Time to progression [ Designated as safety issue: No ]
• Overall survival [ Designated as safety issue: No ]
• Association between clinical response and donor/recipient KIR ligand matching status [ Designated as safety issue: No ]

RATIONALE: Giving chemotherapy, such as cyclophosphamide and fludarabine, and total-body irradiation before a donor natural killer cell infusion helps stop the growth of tumor cells. It also helps stop the patient's immune system from rejecting the donor's natural killer cells. Aldesleukin may stimulate the natural killer cells to kill ovarian, fallopian tube, or primary peritoneal cancer cells. Treating the donor natural killer cells with aldesleukin may help the natural killer cells kill more tumor cells.

PURPOSE: This phase II trial is studying how well giving laboratory-treated donor natural killer cells together with aldesleukin works when given after cyclophosphamide, fludarabine, and total-body irradiation in treating patients with recurrent and/or metastatic ovarian, fallopian tube, or primary peritoneal cancer.

OBJECTIVES:

Primary

• To evaluate the in vivo expansion of an infused allogeneic natural killer (NK) cell product following a preparative regimen comprising cyclophosphamide, fludarabine phosphate, and total-body irradiation in treating patients with recurrent and/or metastatic ovarian, fallopian tube, or primary peritoneal cancer.

Secondary

• To characterize the quantitative and qualitative toxicities of this treatment regimen.
• To estimate disease response (complete or partial response) or clinical benefit (stable disease for > 6 months) as measured by RECIST criteria.
• To estimate time to progression and overall survival.
• To estimate the association between clinical response and donor/recipient KIR ligand matching status.

Tertiary

• To evaluate immune activation of the in vivo expanded haploidentical allogeneic NK cells and its effect on the immune system.

OUTLINE:

• Preparative regimen: Patients receive fludarabine phosphate IV on days -6 to -2 and cyclophosphamide IV on days -5 and -4. Patients also undergo total-body irradiation on day -1.
• Allogeneic natural killer (NK) cell administration and aldesleukin: Patients receive aldesleukin-activated haploidentical allogeneic NK cells IV on day 0. Beginning 4-6 hours after allogeneic NK cell infusion, patients receive aldesleukin subcutaneously (SC) 3 times a week for 6 doses.

Patients achieving any initial response (complete or partial response) or a clinical benefit (stable disease for > 6 months) who progress after 6 months may receive 1 re-treatment course as above.

Blood samples are collected at baseline, on days 0, 7, 14, and 28, and then at 2 and 3 months for cytokine measurements, immunophenotyping, functional analyses, and testing for persistence of donor cells.

After completion of study treatment, patients are followed periodically for at least 1 year.

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cavity Cancer

• Biological: aldesleukin
• Biological: lymphokine-activated killer cells
• Biological: therapeutic allogeneic lymphocytes
• Drug: cyclophosphamide
• Drug: fludarabine phosphate
• Radiation: total-body irradiation

DISEASE CHARACTERISTICS:

• Diagnosis of ovarian, fallopian tube, or primary peritoneal cancer

  • Recurrent and/or metastatic disease
• Measurable disease, defined as ≥ 1.0 cm by RECIST criteria
• Disease progression during or failed to respond to ≥ 2 prior salvage chemotherapy regimens for recurrent and/or metastatic ovarian cancer

• History of brain metastases allowed provided they have been stable for ≥ 3 months after treatment

  • A brain CT scan is required for patients with known brain metastases or with new clinical signs or symptoms of brain metastases at time of study enrollment
• No bone-only metastatic disease
• Related HLA-haploidentical natural killer cell donor available (by at least class I serologic typing)

PATIENT CHARACTERISTICS:

• GOG performance status 0-1
• ANC ≥ 1,000 x 10^9/L
• Platelet count ≥ 80,000 x 10^9/L
• Hemoglobin ≥ 9 g/dL
• Creatinine ≤ 2.0 mg/dL
• Bilirubin ≤ 3.0 mg/dL
• AST and ALT < 5 times upper limit of normal (ULN)
• Alkaline phosphatase < 5 times ULN
• LVEF > 40% (testing required only if symptomatic or prior known impairment)
• Corrected DLCO and FEV_1 > 50% (testing required only if symptomatic or prior known impairment)

• No active infection

  • Must be afebrile, off antibiotics, and have no uninvestigated radiologic lesions (infiltrates or lesions with negative cultures or biopsies after clinically appropriate testing are allowed)
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics
• At least 3 days since prior prednisone or other immunosuppressive medications